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Abstract 
Thyroid cancer is a complex disease requiring management by a large multidisciplinary team.  The 
number of patients with a diagnosis of thyroid cancer is significantly increasing year on year, and 
traditional models of consultant led follow up are no longer sustainable.   Although nurse led cancer 
follow up clinics are becomining increasingly common, thyroid cancer nurse led follow up clinics are 
rare.  An excellent understanding of the disease, treatment and management of risk of disease 
recurrence is essential for safe patient care, and is discussed in this article.  The clinic discussed 
utilises the skill set of head and neck nurse specialists, including psychological support, coping 
strategies for long term side effects of treatment and non-medical prescribing.  A patient survey of 
the service revealed high levels of patient satisfaction and a desire to continue face to face 
consultations rather than telephone clinics. 
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Background - Thyroid cancer 
The last thirty years have seen a rapid increase in the numbers of patients diagnosed with thyroid 
cancer – currently around 3500 cases per year (Cancer Research UK, 2017).  See Figure 1.  Thyroid 
cancer is a very rare disease and accounts for less than 1% of all cancers.  However the incidence of 
thyroid cancer in the UK has increased by 155% since the early 1990s (Cancer Research UK, 2015). In 
2015, 3528 new cases of thyroid cancer were diagnosed in the UK: thyroid cancer affects 
predominantly young women, 35-39 years, and there appears to be little, if any, impact from 
deprivation rates on the incidence of thyroid cancer (Cancer Research UK, 2015).   
Patients typically present with a painless lump at the root of the neck that gradually increases in size.  
Other symptoms can include: 
• a hoarse voice that doesn’t have an obvious reason: the recurrent laryngeal nerve can 
become damaged as a result of cancer invasion which causes a hoarse voice 
• difficulty swallowing: tumour compression of the oesophagus 
• difficulty breathing: tumour compression of the trachea 
• pain in the front of the neck 
and less commonly: 
• flushing of the face: elevation of calcitonin in medullary thyroid carcinoma  
• frequent loose stools or diarrhoea because elevation of calcitonin in medullary thyroid 
carcinoma 
The British Thyroid Association (BTA) Guidelines for the Management of Thyroid Cancer (BTA, 2014) 
are closelt followed by multidisciplinary teams (MDTs) treating patients with thyroid cancer and 
treatment includes surgery to remove the thyroid gland (total thyroidectomy) with removal of any 
suspicious or metastatic lymph nodes in the neck (see Illustration 2).  In some cases a hemi-
thyroidectomy may be sufficient when the cancer is small (less than 1cm) (see Figure 3).  Radioactive 
iodine (radioiodine) is commonly given following surgery in patients who have papillary thyroid 
cancer; however in medullary thyroid cancers radioiodine is not considered as medullary cancers are 
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not sensitive to radioiodine.  In some patients, external beam radiotherapy is given for patients 
considered to be at high risk of cancer recurrence. 
Treatment of thyroid cancer is complex and involves a large MDT at specialised treatment centres. 
There are four types of thyroid cancer; medullary, papillary, follicular, and anaplastic. Less than 1% 
of all thyroid cancers are anaplastic (Cancer Research UK, 2015): it usually affects elderly patients 
who often present via A&E with sudden onset respiratory stridor. Papillary and follicular are often 
grouped together as differentiated thyroid cancer (DTC). Diagnosis is achieved with ultrasound 
guided fine needle for cytology and / or diagnostic hemi-thyroidectomy. Medullary thyroid cancer is 
treated surgically as it is radio-iodine refractive. Thyroid cancer can metastasise via the lymphatic 
system and a lymph node clearance of the front of the neck is sometimes undertaken at the time of 
surgery. If there is any suspicion or confirmation that other nodes in the neck are affected a neck 
dissection is also performed. Post-operative radiotherapy may be used for medullary if there is 
thought to be a high risk of recurrence or incomplete excision, but this treatment modality is rare. 
Approximately 20-25% of patients in this medullary group have a genetic pre-disposition to its 
development. Differentiated thyroid cancer (DTC) is the most common type of thyroid cancer (90%). 
It can be treated by a combination of surgery and radio-iodine. 
Patients are risk stratified at two key stages (BTA, 2014): 
• Following surgery using histopathology results and radiology and TNM staging (T= primary 
tumour size; N= number of affected lymph nodes; M= whether distant metastasis has occurred).  
The decision to offer further treatment is based on these results 
• At 9-12 months following radio-iodine treatment. 
Risk stratification helps the MDT to understand treatment pathways, patient prognosis and follow-
up pathways. 
Follow up 
Current national guidelines state that thyroid cancer has a long natural history where late 
recurrences occur but can be treated successfully with a view to cure or long term survival (BTA, 
2014).  This has placed an increasing burden on consultant teams which follow-up patients for life as 
is currently recommended following treatment. Long term, multi-disciplinary consultant led follow-
up is recommended practice as thyroid cancer is known to recur many years after treatment in 5-
23% of patients (Mitchell et al, 2016).  
Murchie et al (2016) investigated cancer survivors preferences to inform new models of follow-up 
care and found that patients from a number of different cancer sub-sites and found that 
respondents appeared willing to accept follow-up by a specialist nurse, trainee specialist doctor or 
GP provided that they were compensated by other changes in their follow-up, notably greater 
continuity of care.  This mirrors the views of health professionals who are increasingly recognising 
the benefits of nurse-led cancer follow up (Wells, Semple & Lane, 2015). 
Macmillan Cancer Support’s Recovery Package and NHS Improvement highlight the potential 
benefits of risk-stratifying follow up of cancer patients (Macmillan Cancer Support, 2015; NHS 
Improvement, 2016). National policy in the UK from both the Government and Macmillan Cancer 
Support articulates the need for change from the traditional one size fits all consultant led follow up 
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model, to models that are patient centred and holistic (Department of Health et al, 2010).  An 
ambitious strategy was launched by the Independent Cancer Taskforce (Cancer Research UK, 2015) 
which aimed to transform cancer care between 2015 and 2020 including alternative models of 
follow up following cancer treatment. Individual care plans may range from discharge and self-care, 
to monitoring by a specialist nurse or AHP, or continued consultant follow up and monitoring. The 
British Thyroid Association (BTA) also supports alternative models of follow up such as nurse led 
clinics (BTA, 2014). 
Consensus exists amongst the medical profession for follow-up of thyroid cancer patients to detect 
recurrence and second primaries (Simo et al, 2016). However, as the population ages and more 
patients are surviving cancer, traditional models of consultant led follow up are unsustainable. 
Although it is assumed that consultant led follow up is the safest way to detect recurrence and 
second primaries, there is evidence that nurses can safely follow up cancer patients (Moore et al, 
2002). Additionally, nurse-led follow-up has been found to have a positive effect on a patient’s 
quality of life (de Leeuw et al, 2012) and patient satisfaction remains high over time (Berglund et al 
2015). A systematic literature review (Lewis et al 2009) found that continuity of care and unhurried 
consultations are of major importance to patients – something that the thyroid nurse led clinic is 
able to provide. 
The clinic at the Royal Preston Hospital was established in 2013 as a result of a challenge by a 
consultant ENT Surgeon, who felt that the clinical nurse specialist (CNS) team could significantly 
improve the experience of thyroid cancer patients by providing a nurse led clinic for low risk 
patients. A consultant-led clinic runs alongside the nurse-led clinic.  Therefore, if the CNS requires a 
consultant review of a patient with thyroid cancer a second clinic attendance is not required on a 
separate day.  The clinic was established a full year ahead of national guidelines by the BTA. The 
clinic is focused on minimising the risk of recurrent disease using medical management of thyroid 
stimulating hormone (TSH) suppression.  The production of thyroxine from the thyroid gland has 
vital roles in digestion, heart and muscle function.  It is regulated by a constant ‘feedback’ loop.  The 
hypothalamus secretes thyrotropin-releasing hormone (TSR) which in turn stimulates the pituitary 
gland to produce TSH.  When the levels of thyroxine increase the production of TSR and TSH is 
reduced and thereby regulating the level of thyroid hormones in the body (Tortora and Derrickson, 
2017).  It is this mechanism that is used to manage the risk of disease recurrence: by managing the 
dose of levothyroxine (the pharmacological form of thyroxine) the TSH is surpressed so that it 
doesn’t stimulate growth of any thyroid cells (which could potentially be cancerous).   
As patients are followed up for life, there is the opportunity for strong therapeutic relationships to 
develop between CNS and patient.  For example, in addition to managing the risk of cancer 
recurrence in this way, the CNS has the opportunity to explore quality of life issues directly impacted 
by physiological levels of thyroxine.  The potential effect on health status (including fatigue) and 
mood in patients taking TSH-suppressive doses of levothyroxine is well recognised (Samuels et al, 
2014).  Additonally, the CNS appointments are longer than their medical counterparts which gives 
time for discussing strategies for managing fatigue which is extremely common following treatment, 
however there are few evidence based management strategies in post-treatment fatigue 
management (To et al, 2015). 
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Historically, thyroid cancer patients who were in long term follow up would never see the same 
doctor twice (due to the Specialist Registrar rotation), and so at every appointment would have to 
repeat his/her clinical history which was frustrating and by its very nature could not facilitate the 
development of a therapeutic relationship over time. A sound understanding of thyroid cancer and 
its management, including the risk of disease recurrence, is essential in order to safely manage the 
risk of disease recurrence. 
The BTA has key recommendations for follow-up (British Thyroid Association, 2014) which utilise the 
common skillset of a Head and Neck Clinical Nurse Specialist (CNS) (Webber, 2008), however, the 
recommendation includes clinical examination of the neck. United Kingdom national 
multidisciplinary guidelines for the management of thyroid cancer also state that clinical 
examination of the neck must be performed as part of routine follow up (Mitchell et al, 2016).  
Clinical palpation and assessment of neck lumps is not a skill commonly adopted by head and neck 
CNSs. However, at the author’s Trust a Rapid Access Neck Lump Clinic was established in 2003 which 
is, in part, CNS led. Appropriate clinical examination skills were taught to the CNS team and, 
following rigorous assessment by a senior consultant the assessment of necks skill set was signed off 
as competent. This created an ideal opportunity for nurse led follow up of thyroid cancer patients 
that provided the traditional medical skill set necessary to conform to national guidelines but also 
the holistic assessment and support embedded within the CNS role. 
A pro-forma was developed by the team which ensured that all the key clinical information is 
collected and reviewed at every appointment (see illustration). Ultrasound request rights were 
secured for the three CNS’s running the clinic. 
Guidelines on frequency of follow-up were developed and agreed at the local Thyroid NSSG 
(Network Site Specific Group) which are more stringent than the BTA guidelines (6 monthly for 2 
years rather than 1 year, then annually thereafter). 
Before attending the clinic a patient has a surveillance ultrasound scan and routine bloods including 
Thyroid Function Tests and Thyroglobulin (non-stimulated).  The test results, recent clinical history 
and clinical assessment are then analysed and a plan agreed with the patient. The plan aims to 
minimise the risk of cancer recurrence by suppressing the Thyroid Secretory Hormone (TSH) 
between 03-2.0mIU/L using Levothyroxine as stated in the BTA guidelines.  In addition, support for 
patients to manage the long term side effects from treatment is discussed with the patient. 
However, by introducing a pro-forma based assessment tool the opportunity for practising different 
standards of care from one health professional to another reduces significantly.  A patient 
experience survey showed patients value the therapeutic relationship which began at diagnosis and 
then continues throughout treatment and follow up. 
The follow up clinic has diagnosed only one episode of recurrence during its existence: this suggests 
that the model of risk stratification and follow-up is fit for purpose (see case study).  However, as risk 
of recurrence is life long and the clinic has only been in existence for six years further cases of 
recurrence are not unexpected. 
Survey Design  
A simple seven-question anonymous patient satisfaction questionnaire was developed by the 
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authors using Survey Monkey software.  The questionnaire collected both quantitative and 
qualitative data to allow the patients the opportunity to give feedback in free text.  Ethical approval 
was not required as this was an audit of the service. 
Patient population 
The study population included all patients attending the clinic and predominantly females under the 
age of 50 years which reflected the age and sex distribution of patients at diagnosis.   
Data collection  
Over a six week period during Spring 2019, all patients attending clinic were offered the opportunity 
to complete the feedback questionnaire.  All 36 patients agreed to take part.  Following the patients’ 
consulation in clinic, questionnaires were completed electronically on Survey Monkey using an 
electronic tablet:  privacy was given to the patient whilst completing and submitting the survey. 36 









Q1 How satisfied were you with the nurse specialist assessment today? 
Q5 How satisfied were you with the length of the consultation today? 
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Q2 Did the CNS answer all your questions to your satisfaction? 
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The patient experience survey demonstrated that patients are extremely satisfied with the care from 
the CNS.  Some regions undertake telephone follow up clinics for low risk cancer patients.  
Interestingly, 100% of patients who completed the survey would prefer face to face follow up when 
given the choice of telephone or face to face.  Given that parking difficulties for patients attending 
outpatient clinics at the hospital are significant, to have 100% of respondents preferring face to face 
follow-up when given the choice is remarkable and reflects the value of face to face therapeutic 
relationships. Free-text comments included:  
• “It’s always easier to speak face to face, just in case something is not understood and a 
friendly face helps enormously.” 
• “Because they ask me questions I would not think of” 
• “It’s more personal” 
The survey was undertaken before the COVID-19 pandemic, and since then the service has been 
delivered via telephone or video using the NHS ‘Attend Anywhere’ service.  Although not formally 
audited, anecdotal feedback given voluntarily from patients during telephone and video 
consultations suggests they would like to return to face-to-face appointments in the future.  The 
reasons for this need to be explored to understand patient preferences.  A mixed approach, by 
either telephone, video or face to face, informed by individual patient preference, may be the way 
forward after the pandemic. 
When patients were asked how the clinic could be improved the some of the following reponses 
were given: 
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• “I am very happy with my appointments and treatment” 
• “Very good service” 
• “It’s excellent – keep going” 
• “I am very satisfied and pleased to be among the people who can say “thank you” for saving 
my life!  I can’t imagine how you could improve on that!  Grateful thanks.” 
• “It’s very helpful and makes me feel my appointment is important to him” 
• “Excellent staff” 
• “Please ensure that this specialised treatment and help is available for all” 
The above comments are representative of those given in the survey.  However, there were 2 
comments reminding us that waiting times can occasionally be too long:  80% of patients are seen 
within 10 minutes of arrival and 95% within 15 minutes.  When we considered why this may be, the 
longer waiting times occurred when there was a newly diagnosed cancer patient in the consultant 
clinic which runs alongside the thyroid clinic, and the CNS interrupted the thyroid clinic to meet and 
support this patient. 
Unfortunately, local thyroid cancer support groups do not exist: the survey was used to assess 
appetitite for establishment of a support group. 
• 100% of patients were ‘Extremely Satisfied’ with the CNS assessment on the day of clinic. 
• 100% of patients received answers to questions to their satisfaction 
• 100% of patients prefer to see the CNS face to face rather than receive a telephone 
consultation 
• 95% of patients were seen within 15minutes of the appointment time 
• 100 of patients were satisfied with the length of the consultation 
• 52% of patients would like to have a patient support group 
• 52% of patients would attend a support group meeting 
 
Limitations 
The survey was administered at a single hospital, and the number of completed surveys limited, 
therefore the survey findings are not generalisible. Qualitative data obtained in patients’ freetext 
responses were limited, and it is possible that interviews with patients, rather than a questionnaire 
tool, may have encouraged responses in greater depth.  Free text comments are often seen as too 
subjective and unfocused to provide a babsis for action (Welch, 2010). 
The survey was only available on an electronic tablet, and some patients who were not confident 
using the technology could decline to participate. The provision of a postal survey may have 
encouraged these patients to participate. 
 
Conclusion 
The nurse led thyroid cancer follow up clinic is extremely successful for patients and CNSs alike. 
Improving patient care and innovative ways of working were the drivers for the establishment of the 
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clinic in 2013, however, the clinic was established before the National Cancer Strategy (Independent 
Cancer Task Force, 2015) and meets the ambition for more patient centred models of follow up. 
Nurse led cancer follow up clinics are well established, but a concern exists about how future 
demand can be met when this for follow up exceeds the current supply of CNSs. The management of 
thyroid cancer recurrence is complex and whilst some patients may be able to self manage (as 
recommended in Macmillan Cancer Support’s ‘Recovery Package’), no current thyroid guidelines 
advocate this practice.  Some nurses, especially CNSs, are seen as an expensive resource by some, 
yet in this setting, they are a more cost-effective alternative to consultant care, freeing the 
consultant to see new cancer patients or more complex cancer patients. The clinic is a good example 
of how the role of the CNS has developed to meet some of the demands of cancer care in the 21st 
century. 
There is a trend towards telephone consultations in the NHS and has the potential benefits of 
convenience for the patient including the lack of need to travel to the consultation, parking at the 
hospital (a particular issue at the author’s hospital), and no difference in the levels of patient 
satisfaction between face to face and telephone consultations (Hewitt et al, 2010), however, this 
may disadvantage patients with a hearing impairment.   
Declarations of interest: none 
Key points 
• The incidence of thyroid cancer has been rapidly increasing in the last thirty years and most 
commonly affects young women.  Treatment includes surgery, radio-iodine and 
radiotherapy 
• Follow-up of thyroid cancer patients is most commonly in consultant led clinics, however 
national guidelines and initiatives advocate risk stratification of disease recurrence following 
treatment and personalised models of follow up 
• Head and Neck Clinical Nurse Specialists commonly have the necessary skill set to facilitate 
safe follow up of this group of patients, managing risk of disease recurrence (using non-
medical prescribing), long term treatment side effects such as fatigue, and provide 
psychological support 
• Patients are extremely satisfied with the nurse led service and overwhelmingly prefer a face 
to face (rather than telephone) model of follow up and support despite the inconvenience 
and cost that this causes 
CPD reflective questions: 
• How can nurses continue to develop cancer services to meet the needs of patients, 
especially in the light of new challenges such as SARS-CoV-2 (COVID-19)? 
• Do you feel confident having very complex and difficult discussions with patients in a way 
that they can understand? 
• What skills and knowledge will help you to facilitate those conversations? 
• When nurses develop highly specialised services such as the thyroid cancer follow-up clinic, 
how can you successfully undertake succession planning to ensure services continue to meet 
patient need? 
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1- Average number of new cases per year – United Kingdom (Credit: Cancer Research UK.  Used 
with permission) 
 
2- Thyroid cancer in the right lobe and neck nodes 
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Case Study 
James (not his real name) was referred to the nurse led thyroid clinic by a retiring oncologist.  James 
had been in 2 yearly follow up for a number of years.  James was seen in clinic to introduce the CNS 
and begin to establish a therapeutic relationship.  James was referred for bloods and surveillance 
ultrasound scan of the neck and thyroid bed.  Intersetingly, he had not had any ultrasound scans 
conducted for 7 years.  A review of investigations from the previous 5 clinic appointments had 
shown the Thyroglbulin had been detectable but stable (Tg 3ng/mL), but there was no clear plan 
regarding a target Thyroid Stimulating Hormane target range.  Following thyroid cancer, 
thyroglobulin should be undetectable – it is a dimeric protein produced by the follicular cells of the 
thyroid and used entirely within the thyroid gland.  If thyroglobulin is detectable it raises suspicion 
that further disease may be present with local recurrence of the cancer or distant metastases.  
When James was reviewed in clinic with bloods and ultrasound scan the blood test revealed a rising 
thyroglobulin (Tg 5ng/mL).  Following discussion with the consultant a CT chest was requested.  
Interestingly the consultant and the author had recently returned from a conference at which a 
paper was presented that theorised that there is little or no value in undertaking additional 
radiological investigations (other than USS) as recurrence was never detected when thyroglobulin 
<10ng/mL.  However, we were relieved that we chose to ignore the advice as the chest CT revealed 
multiple chest metastases.  James was discussed at the thyroid MDT and offered radio-iodine. 
 
 
